This website is intended for HCP's. Visit the patient site

THE POWER OF TECHNOLOGY.

MODE OF ACTION

ULTHERAPY PRIME uses micro-focused ultrasound technology to create thermal coagulation points (TCPs) at the precise depths of 1.5, 3.0, and 4.5mm, to reach the collagen and elastin rich tissue layers, to create a personalised lift without damaging the skin’s surface.1-3

Its engineering precision promotes delivery of TCPs at optimal, consistent coagulative temperatures of approximately 65°C, initiating the rejuvenation process through collagen denaturation and synthesis for effective, reproducible results.1,3,4

Patients may see some initial lift, but visible results will take about 3 to 6 months after treatment, with continued improvement over a year, as new collagen and elastin form.4-6

PHASE 1:

TEMPORARY INFLAMMATION ASSOCIATED WITH THE HEALING PROCESS
During the initial phase, macrophages engulf and digest injured tissue and release cytokines, which attract fibroblasts.7,8

PHASE 2:

PROLIFERATION
In the proliferation phase, fibroblasts synthesise the newly created type Ill collagen alongside other mediators important to rebuilding the collagen matrix.7,8

PHASE 3:

MATURATION & REMODELING
In the maturation and remodelling phase, type III collagen is replaced by type I collagen, forming tight cross-links with itself and other proteins, leading to a long-term, lifting result.4,7,8

Artist’s renderings are for illustrative purposes only.

INTRODUCE ULTHERAPY PRIME TO YOUR PRACTICE TODAY

Get in touch

REFERENCES

  1. ULTHERAPY PRIME (Instructions for Use)
  2. Fabi SG, et al. J Drugs Dermatol. 2019;18(5):426-432
  3. Fabi SG. Clin Cosmet Investig Dermatol. 2015;5;8:47-52
  4. Werschler WP, Werschler PS. J Clin Aesthet Dermatol. 2016;9(2):27-33.
  5. Brobst RW, et al. Facial Plast Surg Clin N Am. 2014;22:191–202.
  6. Kerscher M, et al. Clin Cosmet Investig Dermatol. 2019;12:71–79
  7. Casabona G, Kaye K. J Drugs Dermatol. 2019;1;18(11):1075-1082.
  8. Gardeazabal L, Izeta A. Exp Dermatol. 2024 Mar;33(3):e15052

M-ULT-UKI-1693 Date of Preparation February 2025